Residual excessive daytime sleepiness in patients treated for obstructive sleep apnea: guidance for assessment, diagnosis, and management

Postgrad Med. 2021 Sep;133(7):772-783. doi: 10.1080/00325481.2021.1948305. Epub 2021 Jul 22.

Abstract

Excessive daytime sleepiness (EDS) affects approximately half of patients with obstructive sleep apnea (OSA) and can persist in some despite normalization of breathing, oxygenation, and sleep quality with primary OSA therapy, such as continuous positive airway pressure (CPAP). EDS is often overlooked and under discussed in the primary care setting and in the follow-up of CPAP-treated patients due to difficult assessment of such a multi-dimensional symptom. This review aims to provide suggestions for procedures that can be implemented into routine clinical practice to identify, evaluate, and manage EDS in patients treated for OSA, including how to appropriately use various self-report and objective assessments along the clinical pathway and options for pharmacotherapy. In addition, examples of when it is appropriate to refer a patient to a sleep specialist for evaluation are discussed.

Keywords: Excessive daytime sleepiness; assessment; clinical practice; pharmacotherapy; sleep medicine.

Publication types

  • Review

MeSH terms

  • Age Factors
  • Body Mass Index
  • Comorbidity
  • Diagnosis, Differential
  • Disorders of Excessive Somnolence / diagnosis*
  • Disorders of Excessive Somnolence / drug therapy*
  • Disorders of Excessive Somnolence / etiology*
  • Disorders of Excessive Somnolence / therapy
  • Health Behavior
  • Humans
  • Life Style
  • Risk Factors
  • Self Report
  • Sleep Apnea, Obstructive / complications*
  • Sleep Apnea, Obstructive / therapy
  • Wakefulness-Promoting Agents / administration & dosage
  • Wakefulness-Promoting Agents / adverse effects
  • Wakefulness-Promoting Agents / therapeutic use*

Substances

  • Wakefulness-Promoting Agents